MAP2K3 and colorectal carcinoma: Results suggested that both drugs, through the AURKA inhibition, induced MKK3 protein degradation hampering the CRC malignancy in tested lines, and revealed a novel mutual dependency between the AURKA and MKK3 proteins, as activated MKK3 sustaining the AURKA gene expression enforce its own protein stability and activation, supporting CRC malignancy.